Adiponectin in relation to childhood myeloblastic leukaemia by Petridou, E et al.
Adiponectin in relation to childhood myeloblastic leukaemia




1,2 and the Childhood Hematology
Oncology Group
1Department of Hygiene and Epidemiology, Athens University Medical School, 75 Mikras Asias Str, Goudi, Athens 11527, Greece;
2Department of
Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA;
3Division of Endocrinology, Diabetes and Metabolism, Department of Internal
Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Adiponectin, an adipocyte-specific secretory protein known to induce apoptosis, has been reported to be inversely related to breast
and endometrial cancers and recently found to inhibit proliferation of myeloid but not lymphoid cell lines. We hypothesised that
adiponectin may be inversely associated with acute myeloblastic leukaemia (AML), but not with acute lymphoblastic leukaemia of B
(ALL-B) or T (ALL-T) cell origin in children. Blood samples and clinical information were collected over the period 1996–2000 from
201 children (0–14 years old) with leukaemia (22 AML, 161 ALL-B and 18 ALL-T cases) through a national network of childhood
Hematology-Oncology units in Greece and from 201 controls hospitalised for minor pediatric ailments. Serum adiponectin levels
were measured under code, at the Beth Israel Deaconess Medical Center, Boston, MA, USA using a radioimmunoassay procedure.
Each of the three leukaemia groups was compared with the control group through multiple logistic regression. Odds ratios (OR) and
95% confidence intervals (95% CI) for an increase of adiponectin equal to 1 s.d. among controls were estimated controlling for
gender, age, as well as for height and weight, expressed in age–gender-specific centiles of Greek growth curves. Adiponectin was
inversely associated with AML (OR¼0.56; 95% CI, 0.34–0.94), whereas it was not significantly associated with either ALL-B
(OR¼0.88; 95% CI, 0.71–1.10) or ALL-T (OR¼1.08; 95% CI, 0.67–1.72). Biological plausibility and empirical evidence point to the
importance of this hormone in the pathogenesis of childhood AML.
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With the exception of ionizing radiation and genetic abnormal-
ities, the aetiology of childhood leukaemia has not yet been fully
elucidated. It also remains unknown whether the principal forms
of childhood leukaemia, namely acute lymphoblastic leukaemia of
B-cell origin (ALL-B), acute lymphoblastic leukaemia of T-cell
origin (ALL-T) and acute myeloblastic leukaemia (AML) have
similar aetiologies and/or pathogenesis. Most aetiologic research
on childhood leukaemia has focused on ALL due to its much
higher frequency in comparison to that of AML (Petridou and
Trichopoulos, 2002; McNally and Eden, 2004; Randolph, 2004).
Adiponectin is an adipocyte-secreted hormone which has been
found to induce apoptosis and suppress angiogenesis (Cao et al,
1999; Brakenhielm et al, 2004). This hormone has also been
inversely associated with both adult forms of cancer that have been
epidemiologically investigated, namely breast cancer (Miyoshi
et al, 2003; Mantzoros et al, 2004b) and endometrial cancer
(Petridou et al, 2003; Dal Maso et al, 2004). In a recent in vitro
study Yokota et al have investigated the functions of adiponectin
in haematopoiesis and found that adiponectin predominantly
inhibits proliferation of myeloid cell lines, and induces apoptosis
in myelomonocytic leukaemia lines, but did not suppress
proliferation of erythroid or lymphoid cell lines. We have thus
hypothesised that adiponectin might be inversely associated with
AML, but not with ALL. We have evaluated this hypothesis by
studying 201 children with incident leukaemia and 201 appropriate
control children enrolled by a nation-wide network of Pediatric
Hematology-Oncology Departments in Greece.
MATERIALS AND METHODS
A national network comprising all six Childhood Hematology-
Oncology Departments operating in Greece has been established
and has coordinated epidemiological research for the last 15 years
(Petridou et al, 1993, 1996). In the present study, we have included
childhood leukaemia cases (0–14 years old) first diagnosed in
Greece during a 5-year period (1996–2000). Children from one of
the two Departments in Thessaloniki, however, were not included
for administrative reasons. Thus, the study was based on 281 cases
of childhood leukaemia diagnosed in five Departments, three in
Athens, one in Thessaloniki and one in Crete. Of these cases, 80
were not included, because informed consent could not be
obtained before the onset of therapy or laboratory samples were
inappropriate or inadequate. These exclusions are unlikely to have
introduced selection bias because it was based on technical and
administrative reasons. Moreover, serum ADP levels could not
impact on patients’ decisions to participate in our study; thus it is
not possible to have any influence on the reported results. Of the
remaining 201 cases of childhood leukaemia, 161 were of B-cell
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yorigin (ALL-B), 18 of T-cell origin (ALL-T) and 22 had AML. We
have not included in the present study cases with Down’s
syndrome, Fanconi anaemia, other predisposing to leukaemia
genetic conditions and children with leukaemia as a second cancer
or cases with a previous history of myelodysplasia.
For each child with leukaemia, a control child of the same
gender and similar age (76 months) was sought among those
concurrently admitted to the Pediatric Departments of the same
Hospitals for minor pediatric ailments. For only 11 of them the
parents were unable or unwilling to provide informed consent and
these were properly substituted. Among the 201 controls, 88 were
admitted for mild respiratory conditions, viral infections or allergy
(bronchitis, asthma, urticaria), 35 for gastrointestinal or genitour-
inary conditions (gastroenteritis, abdominal pain, urinary tract
infections), 31 for nervous system conditions (febrile seizures,
transient loss of consciousness, dizziness, headache), 21 for
injuries including acute poisoning and near drowning, six for
muscle-osteoarticular conditions (arthritis, joint pain) and 20 for
other conditions and malformations (chest pain, paleness, double
urethra).
Informed consent was obtained by the guardians of all children
and the study protocol was approved by the Ethics Committee of
the University of Athens Medical School. The parents of all cases
and controls were interviewed in the hospital wards, in most
instances by the same interviewer. The child’s height and weight
were abstracted from the medical records and transformed into
age–gender-specific centiles, to allow comparisons across different
ages, using growth curves developed for Greek children by the
First Department of Pediatrics of the Athens Medical School
(Chiotis et al, 2003). Information on the type of leukaemia was
abstracted from the medical records and blood samples were
collected during routine clinical procedures before the initiation of
therapy.
All coded samples were centrifuged and frozen sera were sent in
dry ice to the coordinating centre in Athens where they were stored
at  701C prior to being air shipped in one batch to the Beth Israel
Deaconess Medical Center, in Boston, USA. Blinded adiponectin
measurements were performed by a radioimmunoassay procedure
with a sensitivity of 2ngml
 1, and intra-assay coefficient of
variation of o10% as previously described (Petridou et al, 2003;
Dal Maso et al, 2004; Mantzoros et al, 2004b). Average
preservation time was similar for cases and controls, and
adiponectin levels do not systematically change with storage time.
Initially cases of childhood leukaemia, by type of disease, as well
as control children were classified by gender, age and age–gender-
specific centiles of height and weight. Representative values of
adiponectin, by disease status, were subsequently calculated. In
order to study a possible association of adiponectin with any of the
three different types of childhood leukaemia, we modelled the data
through multiple logistic regression in three distinct models using
case/control status as the outcome variable and adiponectin (in
increments of one s.d. of the hormone among controls) as well as
gender, age and age–gender-specific centiles of height and weight
as predictor variables. We have opted for unconditional logistic
regression in order to utilise the adiponectin data from all variable
controls in the crucial analysis concerning AML cases. Adjustment
for covariates chosen as possible predictors of either adiponectin
levels or disease risk (e.g. maternal smoking during pregnancy)
and, thus, as conceivable confounders of the association of
adiponectin levels and childhood leukaemia, have not altered the
results appreciably (data not shown). The SAS statistical package
was used in all analyses (SAS Institute Inc., 1989).
RESULTS
Table 1 shows the distribution of 201 children with childhood
leukaemia by disease type and 201 controls by gender, age and
age–gender-specific centiles of height and weight. Since the gender
and age matching was carried out for leukaemia cases overall
differences in the distribution between controls and cases of the
more rare forms of childhood leukaemia are evident. In the main
analyses, however, gender and age were adjusted for, categorically,
through unconditional logistic regression. Although there were no
apparent differences with respect to height and weight, these
factors were also adjusted for, as ordered variables, in the main
analyses. In the multiple logistic regression analysis, age was also
considered as continuous variable and no change was noted.
Table 2 shows representative values of adiponectin among
children by different types of leukaemia and among control
children. Adiponectin is approximately normally distributed and
Table 1 Distribution of 201 children with leukaemia by type and 201
control children by gender age and age–gender-specific centiles of height
and weight
ALL-B ALL-T AML Controls
Variable N % N % N % N %
Gender
Male 77 47.8 13 72.2 10 45.5 100 49.8
Female 84 52.2 5 27.8 12 54.5 101 50.2
P-value (vs controls; w
2 1df) 0.71 0.07 0.70
Age (years)
o1 2 1.2 0 0.0 3 13.6 4 2.0
1–4 90 55.9 6 33.3 12 54.6 108 53.7
5–9 48 29.8 8 44.5 2 9.1 60 29.9
10+ 21 13.1 4 22.2 5 22.7 29 14.4
P-value for trend (vs controls; w
2 3df) 0.92 0.32 0.01
Height (age–gender-specific centiles)
o3 5 3.1 0 0.0 1 4.6 5 2.5
3–24 23 14.3 3 16.7 2 9.1 26 12.9
25–49 24 14.9 3 16.7 0 0.0 30 14.9
50–74 34 21.1 3 16.7 6 27.2 37 18.4
75–96 54 33.5 7 38.8 10 45.5 70 34.9
97+ 20 13.1 2 11.1 3 13.6 33 16.4
P-value for trend (vs controls; w
2 1df) 0.38 0.80 0.48
Weight (age–gender-specific centiles)
o3 2 1.3 1 5.6 1 4.6 5 2.5
3–24 25 15.5 5 27.8 6 27.2 26 12.9
25–49 38 23.6 2 11.1 5 22.7 37 18.4
50–74 42 26.1 3 16.6 4 18.2 48 23.9
75–96 44 27.3 6 33.3 4 18.2 66 32.8
97+ 10 6.2 1 5.6 2 9.1 19 9.5
P-value for trend (vs controls; w
2 1df) 0.16 0.22 0.06
Table 2 Representative values of adiponectin by type of leukaemia and
controls
Adiponectin (lgml
 1) ALL-B ALL-T AML Controls
Number 161 18 22 201
Median 17.7 16.8 14.8 19.2
Mean 18.6 19.4 15.8 19.4
s.d. 7.8 10.6 7.4 7.9
P-value 0.33 0.96 0.048
P-value derived from t-tests, comparing means between leukaemia types and
controls.
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ythere is evidence in these bivariate analyses that levels of
adiponectin are lower among children with AML than among
apparently healthy controls. In contrast, there is no evidence for an
important difference between control children on the one hand
and children with ALL-B or ALL-T on the other.
In Table 3, we present multiple logistic regression-derived,
adjusted odds ratios (OR) and 95% confidence intervals (CI) for
different types of childhood leukaemia by adiponectin levels,
controlling for gender, age as well as for height and weight in age–
gender-specific centiles. There is no evidence that adiponectin is
associated with either ALL-B or ALL-T. With respect to AML,
however, adiponectin is inversely, significantly and strongly
related to the disease. Weight is also significantly inversely
associated with AML. Weight and height in age–gender-specific
centiles are not strongly correlated among controls (Spearman’s
r¼0.35) so that colinearity is not a major problem. Adjusting only
for height or only for weight does not materially change the results.
Thus, the OR for AML in relation to adiponectin, controlling for
gender, age and for height only or weight only are: 0.61 (95% CI,
0.37–0.99) and 0.55 (95% CI, 0.34–0.92), respectively. Models, in
which body weight and height were introduced as continuous
variables (single centile increments), generated similar results
(data not shown).
DISCUSSION
In a nation-wide case–control study in Greece, we found evidence
that adiponectin is inversely related to the risk of childhood AML,
whereas no such evidence was found with respect to other forms of
acute childhood leukaemia. These findings are in line with the
working hypothesis generated by a previous report that adipo-
nectin, a hormone that induces apoptosis, inhibits proliferation of
myeloid, but not of lymphoid, cell lines (Yokota et al, 2000).
Adiponectin, also called gelatin-binding protein-28, is a 244
amino-acid protein secreted exclusively from white adipose tissue,
mainly visceral adipose tissue, to the amount of which it is
inversely related (Motoshima et al, 2002). Adiponectin acts
principally as an insulin sensitiser; it is inversely associated with
parameters of adult obesity and has anti-inflammatory and
antiatherogenic effects (Arita et al, 1999; Ouchi et al, 1999; Yokota
et al, 2000; Ouchi et al, 2001; Motoshima et al, 2002; Cnop et al,
2003; Gavrila et al, 2003). Four epidemiological studies on
adiponectin in relation to cancer have been undertaken among
adults and all four have pointed to inverse associations of the
hormone with breast cancer (Miyoshi et al 2003; Mantzoros et al
2004b) and endometrial cancer (Petridou et al, 2003; Dal Maso
et al, 2004), notably with the postmenopausal forms of the two
diseases. Importantly, adiponectin has been reported to induce
apoptosis through activation of members of the caspase group of
apoptotic enzymes (Brakenhielm et al, 2004) including apoptosis
in myelomonocytic leukaemia lines and to predominantly inhibit
proliferation of myeloid but not of erythroid or lymphoid cell
lines. Treatment of acute myelomonocytic leukaemia lines with
adiponectin induces the appearance of subdiploid peaks and
oligonucleosomal DNA fragmentation. Moreover, adiponectin
regulates inflammatory responses negatively through at least two
mechanisms: inhibition of growth of macrophage precursors and
suppression of mature macrophage functions (Yokota et al, 2000).
Exclusion of cases and controls from a particular catchments
area restricts the study base but should not, by itself, compromise
validity. Case ascertainment in our investigation was population
based and exclusions were based on administrative or technical
reasons that are unlikely to have introduced selection bias. Since
blood samples were necessary, we opted for inclusion of hospital
controls, which were carefully matched to cases, whereas their
admission diagnoses are not known to be related with the principal
exposure variable, namely adiponectin. Consequently, there were
very few refusals for cooperation among the guardians of both the
cases and controls. Adiponectin measurements were blindly
performed in a certified laboratory and none of the diagnoses of
control subjects have been associated with increased adiponectin
levels.
We did not control for components of the insulin-like growth
factor (IGF) system; the limited existing evidence for this system
refers to ALL rather than AML (Ross et al, 1996; Petridou et al,
2000) and the association between adiponectin and IGF-1 in
children is not strong enough to generate considerable confound-
ing (Mantzoros et al, 2004a). Control for height, which is positively
and weight, which is inversely associated with adiponectin levels
(Mantzoros et al, 2004a), was carried out by using the
corresponding age–gender-specific centiles in growth curves
among Greek children (Chiotis et al, 2003), thus allowing fine
adjustment despite the variable ages of cases and controls ranging
between 0 and 14 years of age. We have not controlled for birth
weight, both because the evidence for it being associated with
childhood leukaemia risk refers mostly to ALL (Hjalgrim et al,
Table 3 Multiple logistic regression-derived, adjusted odds ratios (OR)
and 95% confidence intervals (95% CI) for different types of childhood
leukaemia by anthropometric variables and adiponectin levels
Variable Category or increment OR 95% CI P-value
Model 1: ALL-B cases and 201 controls
Gender
Male Baseline
Female 1.11 0.73 1.69 0.62
Age (years)
o5 Baseline
5–9 0.88 0.54 1.43 0.60
10–14 0.75 0.39 1.44 0.39
Height centile
a
1 category more 0.97 0.82 1.15 0.71
Weight centile
a
1 category more 0.88 0.73 1.06 0.19
Adiponectin
1s.d. (among controls) 0.88 0.71 1.10 0.26
Model 2: ALL-T cases and 201 controls
Gender
Male Baseline
Female 0.40 0.13 1.16 0.09
Age (years)
o5 Baseline
5–9 2.17 0.69 6.76 0.18
10–14 2.50 0.63 9.89 0.19
Height centile
a
1 category more 1.10 0.73 1.66 0.64
Weight centile
a
1 category more 0.82 0.54 1.24 0.34
Adiponectin
1s.d. (among controls) 1.08 0.67 1.72 0.76
Model 3: AML cases and 201 controls
Gender
Male Baseline
Female 1.21 0.48 3.07 0.68
Age (years)
o5 Baseline
5–9 0.18 0.04 0.84 0.03
10–14 0.87 0.26 2.91 0.81
Height centile
a
1 category more 1.32 0.88 1.98 0.18
Weight centile
a
1 category more 0.61 0.41 0.89 0.01
Adiponectin
1s.d. (among controls) 0.56 0.34 0.94 0.03
aAge- and gender-specific centiles.
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y2003, 2004), and to avoid in the small data set of AML, the
consequences of the ‘reversal paradox’ phenomenon generated
when body weight, which is related to birth weight, is found to be a
strong predictor of the disease, as was the case in our study (Tu
et al, 2005). Children with leukaemia and control children were
generally taller and heavier than predicted from the growth curves
for Greek children (Chiotis et al, 2003) but this does not affect the
ability to control confounding through use of the corresponding
age–gender-specific centiles in these scales. MacInnis et al (2005)
reviewed among other issues that risk of myeloid leukaemia
among adults 27–75 years old, was positively associated with body
mass index whereas lymphoproliferative malignancies and sub-
groups showed little relationship with body size. We have not been
able to document in this data set this association of weight and
childhood leukaemia in the univariate analysis. It remains to be
investigated whether these divergences are imposed by the small
size of our study or differences in the biology between children and
older adults. A possible explanation could be that adult height,
BMI etc. reflect the life-long effect of the IGF system which also
increases risk for leukaemia whereas in children the exposure to
the IGF system is not long enough to show positive associations.
The strong inverse association of childhood AML with weight that
was found in the multivariate analysis of our study has not been
previously documented in childhood. Irrespective of whether it is
genuine or not, it should not confound the association of
adiponectin with AML, given that it is appropriately controlled for.
In conclusion, we have found biologically plausible and
empirically strong evidence that among children, adiponectin
levels are inversely associated with AML, in contrast to other types
of childhood leukaemia. Although adiponectin has generally been
considered as a hormone-modulating insulin resistance-related
phenomenon in adult life (Arita et al 1999; Stefan et al, 2002; Cnop
et al, 2003; Gavrila et al, 2003) the very high levels of this hormone
in early life (Mantzoros et al, 2004a) suggest an important role of
adiponectin during this period as well. Our in vivo data in
combination to the experimental findings by Yokota et al suggest
that adiponectin may have a specific role in leukaemia which needs
to be explored further in the future. Since there were only 22
children with AML in our study, an unavoidable consequence of
the rarity of the disease and the requirement for obtaining blood
samples from very young children, our results cannot be
considered as conclusive. If confirmed, however, they may provide
a unique insight on the pathogenesis of childhood AML and on the
early life physiological and pathophysiological role of adiponectin.
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